Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Momelotinib dihydrochloride by GSK for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Data Insights
Momelotinib dihydrochloride by GSK for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...